NCT01011972 - A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions

Neoplasm Metastasis

Interventions

DRUG

XMT-1107

6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops

Trial Locations (4)

University of MD Greenbaum Cancer Center, Baltimore

Sarah Cannon Research Institute (SCRI), Nashville

Dana Farber Cancer Institute (DFCI), Boston

Beth Israel Deaconess Medical Center (BIDMC), Boston